Inbred CBA/H mice are susceptible to radiation-induced acute myeloid leukemia (r-AML), and C57BL/6 mice are resistant. A genome-wide screen for linkage between genotype and phenotype (r-AML) of 67 affected (CBA/H × C57BL/6)F1 × CBA/H backcross mice has revealed at least 2 suggestive loci that contribute to the overall lifetime risk for r-AML. Neither is necessary or sufficient for r-AML, but relative risk is the net effect of susceptibility (distal chromosome 1) and resistance (chromosome 6) loci. An excess of chromosome 6 aberrations in mouse r-AML and bone marrow cells up to 6 months after irradiation in vivo suggests the locus confers a proliferative advantage during the leukemogenic process. The stem cell frequency regulator 1 (Scfr1) locus maps to distal chromosome 1 and determines the frequency of hemopoietic stem cells (HSCs) in inbred mice, suggesting that target size may be one factor in determining the relative susceptibility of inbred mice to r-AML.

Cancer is the result of the accumulation of genetic lesions (mutations) in a single cell over time. The lifetime relative risk for cancer therefore increases with age and is determined by the mutation rate, the number of genetic lesions required for malignant transformation, the number of target cells, and intercurrent mortality. Exposure to a carcinogen or the inactivation of gene(s) involved in maintaining genetic stability increases the mutation rate and the probability of malignant transformation. There is also a genetic component that determines relative susceptibility to de novo or induced cancer, and though this is exemplified in the germline transmission of rare, highly penetrant alleles in familial cancer predisposition syndromes, there is increasing evidence that a high proportion of cancers arise in a susceptible subpopulation that carries low-penetrance gene(s).1-3 

Studies of Japanese atomic bomb survivors and of radiotherapy and chemotherapy patients have shown that the main long-term health consequence of exposure is acute myeloid leukemia (AML) and myelodysplasia (MDS). Radiation- and therapy-related acute myeloid leukemias (r-AML and t-AML) are clonal malignancies that arise in most cases from a multipotent hemopoietic stem cell (HSC) and commonly exhibit allelic loss (5q− or monosomy 7), and 10% to 15% of newly diagnosed cases of 5q− or monosomy 7 AML/MDS arise in patients with a history of chemotherapy or radiotherapy.4-8 The extensive use of combination chemotherapy/radiotherapy and/or autologous stem cell transplantation has increased long-term cancer survival, but this has resulted in a 1.5% to 24% cumulative risk for secondary t-AML up to 10 years after treatment, depending on the primary cancer and therapy.5,7-10 Efforts to elucidate the genetic factors that modulate susceptibility to therapy-related AML have concentrated on enzymes involved in carcinogen detoxification, and polymorphic variations in the genes encoding NAD(P)H:quinone oxidoreductase, cytochrome P450 3A4, epoxide hydrolase, and glutathione S-transferase, found to be associated with susceptibility to induced AML.11-15 

r-AML in inbred CBA/H mice is widely considered the most appropriate mouse model of human r-AML. Mouse r-AMLs arise after a long latency (mean latency, 480 days after irradiation), indicating that malignant transformation of the target HSC is a multistage process and there is a low (less than 0.1%) incidence of de novo AML in control CBA/H mice.16,17 A curvilinear radiation dose–response curve in mice and humans is composed of an initial increase in AML risk according to (dose),2 followed by a decrease at higher doses,6,16 and is presumably the net result of 2 opposing dose-dependent processes—mutation induction and cell death. In contrast, inbred C57BL/6 mice are susceptible to radiation-induced thymic lymphoma, a thymus-dependent T-cell malignancy that has no human counterpart,18 and C57BL/6 mice can be considered to be resistant to r-AML.

The differences in susceptibility to r-AML in the CBA/H and C57BL/6 inbred mouse strains can be exploited in genetic linkage analyses to map r-AML susceptibility or resistance loci as the first step in the identification of the gene(s) involved. The lifetime incidence of r-AML in 3 Gy X-irradiated CBA/H mice is approximately 20%, but the incidence of r-AML in 3 Gy X-irradiated (CBA/H × C57BL/6)F1 and F1 backcross and F1 intercross mice is approximately 7%.16 17 r-AML susceptibility is a complex polygenic and partially dominant mouse genetic trait, and the risk following exposure is dependent on genetic background. We have therefore carried out a genome-wide screen for linkage between phenotype (r-AML) and genotype in affected and unaffected 3 Gy X-irradiated (CBA/H × C57BL/6)F1 × CBA/H backcross mice and identified at least 2 suggestive loci on chromosomes 1 and 6. Compared with the (CBA/H × C57BL/6)F1 × CBA/H backcross cohort as a whole, the loci individually increase the relative risk for r-AML by approximately 2-fold, suggesting that r-AML susceptibility in mice is determined by at least 2 low-penetrance genetic loci in the inbred mouse genetic backgrounds used in this study.

Because the long-term repopulating HSC (LT-HSC) is the target cell in radiation-leukemogenesis, the susceptibility/resistance gene(s) products must either have a role in the regulation of LT-HSCs or their response to ionizing radiation, or they must confer a proliferative advantage during the radiation leukemogenic process. An excess of chromosome 6 aberrations in r-AMLs and irradiated bone marrow cells implicates the locus in preleukemic cell proliferation. The stem cell frequency regulator 1 (Scfr1) locus maps to the r-AML–susceptibility locus on distal chromosome 1, so genetically determined target size (LT-HSC numbers) may be one factor in the susceptibility to induced AML.

Mouse irradiations

CBA/H and C57BL/6 mice were from the Harwell colony, and DBA/2 and BALB/c mice were from Harlan UK Limited. Eight- to 12-week-old (CBA/H × C57BL/6)F1 × CBA/H mice were exposed to a single acute dose of 3.0 Gy x-rays at 0.5 Gy/min (constant potential, 250 kV; 1.2 mm Cu). Animal studies were carried out under guidance issued by the Medical Research Council in its publication, Responsibility in the Use of Animals for Medical Research (July 1993), and Home Office Project license no. PPL 30/689 and 30/1272.

Moribund mice were killed by cervical dislocation. Blood and bone marrow smears were taken for microscopic analyses, and tails, leukemic spleens, and kidneys were snap frozen. DNA was prepared from control (tail, kidney, or both) and leukemic spleen essentially as described.17 19 

Leukemia diagnosis

Myeloid leukemias were initially diagnosed by leukemic blood cell morphology, and leukemic spleen was then further analyzed for immunoglobulin heavy chain (IgH) gene rearrangements and for the expression of lineage-specific/restricted markers to identify r-AML and early pre-B lymphomyeloid (L-ML) leukemias.17 19 

Genome-wide screen for linkage

Microsatellite primer sequences were from the Whitehead Institute,20 and genetic positions were from the 2000 Chromosome Committee Reports (Jackson Laboratory21). Five hundred eighty-seven microsatellite markers across the 19 mouse autosomes were screened for informative polymorphisms in the inbred CBA/H and C57BL/6 mice. One hundred thirty-eight were identified to give a genome-wide screen at approximately 20–centimorgan (cM) intervals. Statistical significance of excess heterozygosity or homozygosity at individual microsatellite markers in the affected mice was evaluated using the χ2test for homogeneity and was compared with unaffected mice using the χ2 test of independence.22 Relative risk (RR) was estimated essentially as described.23 

Leukemia incidence in backcross mice

The lifetime incidence of r-AML in 3 Gy X-irradiated CBA/H mice is approximately 20%, whereas it is undetectable in X-irradiated C57BL/6 mice.16-18 We have previously shown that there is no statistically significant difference (P = .3) in the proportions of mice with r-AML in irradiated (CBA/H × C57BL/6)F1, F1 backcross, and F1 intercross mice (approximately 7% lifetime incidence), but they all differ significantly (P = .0000013) from the r-AML incidence in the parental CBA/H strain.17 To further elucidate the complex genetics underlying r-AML susceptibility in CBA/H mice, 1087 (CBA/H × C57BL/6)F1 × CBA/H mice (F1 × CBA/H) were exposed to 3 Gy x-rays, and causes of death were determined over their lifetimes. Sixty-seven r-AMLs were diagnosed.

Genetic linkage analysis

Fifty-eight to 67 affected mice were genotyped in a genome-wide screen of the 19 autosomes at intervals smaller than 22 cM using polymorphic chromosome-specific microsatellite markers (Table1).

Table 1.

Genome-wide genetic linkage analysis of affected (CBA/H × C57BL/6)F1 × CBA/H backcross mice

ChromosomeChromosome
length, cM*
No. of
markers
Mean interval,
cM ± SD
Maximum χ2
(P < .05)1-153
r-AML aberration incidence, %1-155
MarkerTrisomyMonosomy
127 17 7.1 ± 5.7 11.1 (.00086) 4.0 6.0 
114 10 10.4 ± 6.8 3.89 (.49) 95 NA NA 
95 13.6 ± 3.4 0.54 14.9 2.3 
84 10 7.6 ± 5.4 5.42 (.02) 10.8 1.3 
92 13.1 ± 2.6 3.36 8.5 4.0 
75 11 6.3 ± 4.9 11.1 (.00086) 17 15.0 1.5 
74 12.2 ± 7.4 1.06 8.5 
82 11.0 ± 6.0 1.03 
74 12.3 ± 5.2 0.96 17 2.0 
10 77 9.6 ± 4.4 1.8 8.5 
11 80 8.8 ± 5.3 2.6 10.8 
12 61 15.3 ± 3.3 0.37 3.4 
13 80 11 6.7 ± 6.4 6.64 (.01) 6.4 0.8 
14 69 11.5 ± 4.7 0.37 
15 81 13.5 ± 5 1.8 14.9 7.1 
16 72 12.1 ± 5.1 2.18 7.4 2.0 
17 58 8.3 ± 6.2 2.52 3.2 1.4 
18 60 8.4 ± 4.7 1.28 3.2 
19 56 6.2 ± 2.6 2.97 1.1 2.0 0.8 
 Total = 1511 Total = 138      
ChromosomeChromosome
length, cM*
No. of
markers
Mean interval,
cM ± SD
Maximum χ2
(P < .05)1-153
r-AML aberration incidence, %1-155
MarkerTrisomyMonosomy
127 17 7.1 ± 5.7 11.1 (.00086) 4.0 6.0 
114 10 10.4 ± 6.8 3.89 (.49) 95 NA NA 
95 13.6 ± 3.4 0.54 14.9 2.3 
84 10 7.6 ± 5.4 5.42 (.02) 10.8 1.3 
92 13.1 ± 2.6 3.36 8.5 4.0 
75 11 6.3 ± 4.9 11.1 (.00086) 17 15.0 1.5 
74 12.2 ± 7.4 1.06 8.5 
82 11.0 ± 6.0 1.03 
74 12.3 ± 5.2 0.96 17 2.0 
10 77 9.6 ± 4.4 1.8 8.5 
11 80 8.8 ± 5.3 2.6 10.8 
12 61 15.3 ± 3.3 0.37 3.4 
13 80 11 6.7 ± 6.4 6.64 (.01) 6.4 0.8 
14 69 11.5 ± 4.7 0.37 
15 81 13.5 ± 5 1.8 14.9 7.1 
16 72 12.1 ± 5.1 2.18 7.4 2.0 
17 58 8.3 ± 6.2 2.52 3.2 1.4 
18 60 8.4 ± 4.7 1.28 3.2 
19 56 6.2 ± 2.6 2.97 1.1 2.0 0.8 
 Total = 1511 Total = 138      
*

Chromosome length.21 

Number of chromosome-specific polymorphic microsatellite markers used.

Mean interval between markers on chromosome.

F1-153

Maximum χ2 values were obtained in a test for excess homozygosity or heterozygosity in affected mice. Only values forP < .05 are shown.

F1-155

Incidence (%) of clonal chromosomal aberrations in 94 to 147 mouse r-AMLs36-40 involving marker chromosomes containing translocations/deletions, trisomy, or monosomy.

Sex chromosomes were not analyzed because susceptibility to r-AML is not sex linked.17 In the first instance, excess homozygosity or heterozygosity was estimated using the χ2test of homogeneity, and genetic markers that gave a χ2value of less than 1.0 were excluded. Genetic markers that gave a χ2 value of more than 1.0 were examined in further detail by genotyping all affected mice at the marker and at additional markers on either side. As illustrated in Table 1, linkage between genotype and phenotype was observed with more than 99.9% pointwise probability on chromosomes 1 (excess homozygosity) and 6 (excess heterozygosity), and weaker linkage (95%-99% probability) was observed on chromosomes 4 (excess heterozygosity) and chromosomes 2 and 13 (excess homozygosity). However, only the chromosome 1 and 6 loci meet the criterion for suggestive linkage in a backcross analysis.24 

Two hundred eighty-eight to 357 mice of the 1020 irradiated F1 × CBA/H cohort that died of other causes (DOC) were also genotyped at the chromosomal intervals of interest to exclude segregation distortion and to test for the enrichment of specific genotypes in the affected mice using the χ2 test of independence. As illustrated in Table 2, a comparison of the affected and unaffected (DOC) mice reveals more than 99% confidence of linkage on chromosomes 1 (D1Mit150) and 6 (D6Mit384).

Table 2.

Genetic linkage analysis: chromosomes 1 and 6

MarkercMAffected mice, AMLDOC2-bχ2P
Het/Hom2-aχ2PHet/Hom2-aχ2
D1Mit231 12 32/35 0.14 — 177/160 0.86 0.5 — 
D1Mit527 19.5 29/37 0.96 — 176/153 1.6 1.99 — 
D1Mit123 21 29/37 0.96 — 73/69 0.11 0.99 — 
D1Mit21 32.8 28/37 1.2 — 164/173 0.24 0.68 — 
D1Mit303 34.8 29/38 1.2 — 60/81 3.13 0.01 — 
D1Mit435 36.9 28/39 1.8 — 60/82 3.41 0.01 — 
D1Mit181 42 29/37 0.96 — 67/82 1.51 0.02 — 
D1Mit136 59.6 32/35 0.13 — ND
 
— — 
D1Mit187 62 29/38 1.2 — 158/176 0.97 0.68 — 
D1Mit194 71.5 25/41 3.89 .048 151/175 1.77 1.6 — 
D1Mit425 81.6 23/42 5.59 .018 152/176 1.75 2.66 — 
D1Mit15 87.9 22/45 8.00 .0047 183/186 0.02 6.48 .011 
D1Mit111 92.3 20/46 10.45 .0012 162/172 0.3 7.52 .0061 
D1Mit150 100 20/47 11.11 .00086 173/184 0.34 8.06 .0045 
D1Mit116 100.5 25/42 4.33 .038 161/168 0.15 3.03 .082 
D1Mit223 106.3 29/38 1.2 — 166/174 0.19 0.69 — 
D6Mit1 2.8 35/32 0.13 — 154/169 0.7 0.46 — 
D6Mit268 15.6 42/45 4.33 .038 154/168 0.61 4.9 .027 
D6Mit74 20.5 46/21 9.49 .002 160/175 0.67 9.9 .0017 
D6Mit93 26.3 46/21 9.49 .002 158/176 0.97 10.33 .0013 
D6Mit384 27.5 47/20 11.11 .00086 153/179 2.09 13.13 .0003 
D6Mit17 30.3 46/21 9.49 .002 146/186 4.82 13.72 .0002 
D6Mit188 32.5 46/21 9.49 .002 150/180 2.73 12.13 .0005 
D6Mit102 38.5 46/21 9.49 .002 144/185 5.11 13.93 .00019 
D6Mit55 49.7 42/25 4.33 .038 153/181 2.35 6.36 .012 
D6Mit198 67 32/35 0.13 — 151/177 2.06 0.85 — 
D6Mit201 74.1 32/35 0.13 — ND
 
 — — 
MarkercMAffected mice, AMLDOC2-bχ2P
Het/Hom2-aχ2PHet/Hom2-aχ2
D1Mit231 12 32/35 0.14 — 177/160 0.86 0.5 — 
D1Mit527 19.5 29/37 0.96 — 176/153 1.6 1.99 — 
D1Mit123 21 29/37 0.96 — 73/69 0.11 0.99 — 
D1Mit21 32.8 28/37 1.2 — 164/173 0.24 0.68 — 
D1Mit303 34.8 29/38 1.2 — 60/81 3.13 0.01 — 
D1Mit435 36.9 28/39 1.8 — 60/82 3.41 0.01 — 
D1Mit181 42 29/37 0.96 — 67/82 1.51 0.02 — 
D1Mit136 59.6 32/35 0.13 — ND
 
— — 
D1Mit187 62 29/38 1.2 — 158/176 0.97 0.68 — 
D1Mit194 71.5 25/41 3.89 .048 151/175 1.77 1.6 — 
D1Mit425 81.6 23/42 5.59 .018 152/176 1.75 2.66 — 
D1Mit15 87.9 22/45 8.00 .0047 183/186 0.02 6.48 .011 
D1Mit111 92.3 20/46 10.45 .0012 162/172 0.3 7.52 .0061 
D1Mit150 100 20/47 11.11 .00086 173/184 0.34 8.06 .0045 
D1Mit116 100.5 25/42 4.33 .038 161/168 0.15 3.03 .082 
D1Mit223 106.3 29/38 1.2 — 166/174 0.19 0.69 — 
D6Mit1 2.8 35/32 0.13 — 154/169 0.7 0.46 — 
D6Mit268 15.6 42/45 4.33 .038 154/168 0.61 4.9 .027 
D6Mit74 20.5 46/21 9.49 .002 160/175 0.67 9.9 .0017 
D6Mit93 26.3 46/21 9.49 .002 158/176 0.97 10.33 .0013 
D6Mit384 27.5 47/20 11.11 .00086 153/179 2.09 13.13 .0003 
D6Mit17 30.3 46/21 9.49 .002 146/186 4.82 13.72 .0002 
D6Mit188 32.5 46/21 9.49 .002 150/180 2.73 12.13 .0005 
D6Mit102 38.5 46/21 9.49 .002 144/185 5.11 13.93 .00019 
D6Mit55 49.7 42/25 4.33 .038 153/181 2.35 6.36 .012 
D6Mit198 67 32/35 0.13 — 151/177 2.06 0.85 — 
D6Mit201 74.1 32/35 0.13 — ND
 
 — — 

Het/Hom indicates the heterozygous-homozygous ratio;

F2-a

χ2, χ2 test of homogeneity;

F2-b

χ2, χ2 test of independence for affected vs unaffected mice; and ND, not determined. Only values for P < .05 are shown; otherwise — appears.

The excess homozygosity detected on chromosome 2 (D2Mit237) in the affected mice was not significantly different than the D2Mit237 genotype of 272 unaffected mice (P = .28), so linkage to proximal chromosome 2 is excluded (data not shown). Comparison of the affected and unaffected mice using the χ2 test of independence indicates that linkage at chromosomes 4 (D4Mit292;P = .021) and 13 (D13Mit248; P = .043) cannot be excluded. Given the weak penetrance of r-AML (approximately 7% lifetime incidence) in the F1 and F1 × CBA/H backcross mice and the relatively low numbers of affected mice analyzed, the statistical significance achieved is remarkable, with minimum P values occurring at D1Mit150 and D6Mit384 (Table 2).

Neither locus is essential for r-AML induction in the backcross mice. For example, compared with the 67 affected F1 × CBA/H mice, the RR of r-AML in the F1 × CBA/H mice that are homozygous at D1Mit150 on chromosome 1 is 2.17 (P = .0072), and the RR for excess heterozygosity on chromosome 6 is 2.75 (P = .00046). To determine whether each locus contributes additively to r-AML risk, the 4 genotype combinations for the most informative loci on chromosomes 1 (D1Mit150; 1hom or 1het) and 6 (D6Mit384; 6hom or 6het) were assessed in the affected mice and in 322 mice that died of other causes. As illustrated in Table3, the χ2 test of homogeneity reveals no statistically significant deviation from the 1:1:1:1 ratio expected for the 4 genotype combinations in unaffected DOC mice (P = .57). In contrast, the affected mice do show a statistically significant deviation from the expected (P = .00013). The χ2 test of independence reveals a statistically significant difference of the relative proportions of the 4 genotypes in the affected mice compared with the unaffected mice (χ2 = 18.64; df = 3;P = .000325), and RR estimates indicate that this statistical significance is driven by enrichment of the most favored 1hom6het genotype (RR = 2.99) and by depletion of the least favored 1het6homgenotype (RR = 0.27) in the affected mice (Table 3).

Table 3.

Genotypes of affected vs unaffected mice at chromosomes 1 (D1Mit150, 1hom and 1het) and 6 (D6Mit384; 6hom and 6het)

1hom1hom1het1hetχ2P
6hom6het6het6homdf= 3
AML, n = 67 16 31  15  5    21.04 .00013 
DOCs, n = 322 91 77  74 80     2.01 .57  
RR —  2.99 —   .27 — — 
  P = .000079  P = .006   
1hom1hom1het1hetχ2P
6hom6het6het6homdf= 3
AML, n = 67 16 31  15  5    21.04 .00013 
DOCs, n = 322 91 77  74 80     2.01 .57  
RR —  2.99 —   .27 — — 
  P = .000079  P = .006   

Unaffected mice were DOC mice.

— indicates not significant.

During the course of these studies, 54 early pre-B mixed-lineage lymphomyeloid leukemias (L-MLs) were diagnosed19 in the irradiated backcross mice. The r-AML and L-ML loss of heterozygosity profiles on chromosomes 2 and 4 differ,19 suggesting that they represent 2 distinct hemopoietic malignancies, and mice affected with L-ML are included in the unaffected mice that died of other causes (Tables 2-3). However, further evidence to support the proposition that 2 distinct leukemogenic processes are involved can be inferred when the 4 genotype combinations for the most informative loci on chromosomes 1 (D1Mit150; 1hom or 1het) and 6 (D6Mit384; 6homor 6het) were compared in r-AML– and L-ML–affected mice. As shown in Table 4, the χ2test of homogeneity reveals no statistically significant deviation from the 1:1:1:1 ratio expected for the 4 genotype combinations in L-ML–affected mice (P = .28), and the χ2test of independence reveals a statistically significant difference of the relative proportions of the 4 genotypes in the r-AML– and L-ML–affected mice (χ2 = 14.6; df = 3;P = .0022). RR estimates indicate that this statistical significance is again driven by the enrichment of the most favored r-AML 1hom6het genotype (RR = 3.01) and depletion of the least favored r-AML 1het6homgenotype (RR = 0.176) in the r-AML–affected mice, further evidence that 2 distinct leukemogenic processes are involved.

Table 4.

Genotype of r-AML– and L-ML–affected mice at chromosomes 1 (D1Mit150, 1hom and 1het) and 6 (D6Mit384; 6hom and 6het)

1hom1hom1het1hetχ2P
6hom6het6het6homdf= 3
AML, n = 67 16 31  15  5     21.04 .00013 
L-ML, n = 54 12 12  13 17      1.18 .28  
RR —  3.01 —   .176 — — 
  P = .007  P = .0015   
1hom1hom1het1hetχ2P
6hom6het6het6homdf= 3
AML, n = 67 16 31  15  5     21.04 .00013 
L-ML, n = 54 12 12  13 17      1.18 .28  
RR —  3.01 —   .176 — — 
  P = .007  P = .0015   

— indicates not significant.

Because the lifetime incidence of r-AML in the F1 × CBA/H mice as a whole is 6.7% and the F1 × CBA/H subpopulation with the most favored 1hom6het genotype has a 2.99 RR, the incidence of r-AML in the hybrid 1hom6hetgenotype F1 × CBA/H mouse subpopulation is similar to the 20% lifetime r-AML incidence in the parental inbred CBA/H strain.16 17 

The r-AML–susceptible CBA/H and resistant C57BL/6 inbred mouse strains have been exploited in a genome-wide genetic linkage analysis of (CBA/H × C57BL/6)F1 × CBA/H backcross mice to identify at least 2 suggestive loci (chromosomes 1 and 6), each of which makes a modest approximately 2-fold contribution to the RR of r-AML in the (CBA/H × C57BL/6)FI × CBA/H backcross mice following exposure to 3 Gy x-rays. Together, a RR of 3 for both genotypes accounts for the difference in the lifetime r-AML incidence in the irradiated F1 × CBA/H backcross cohort as a whole (6.7% incidence) and in the irradiated parental inbred CBA/H mouse strain (20% incidence).

Although the results of the approximately 1500 cM genetic linkage analysis has focused attention on 2 suggestive, approximately 7-cM chromosomal intervals, it is self-evident that neither is necessary nor sufficient for r-AML and that other low-penetrance genes are clearly involved. The statistical power of the current study of (CBA/H × C57BL/6)F1 × CBA/H backcross mice is constrained by the low (approximately 7%) lifetime incidence of r-AML in the 1037 X-irradiated mice analyzed. For example, there is weak evidence that loci on chromosomes 4 and 13 may also be involved (Table 1), but the statistical power is insufficient to satisfy the accepted criterion for suggestive linkage.24 Nevertheless, the intervals on mouse chromosomes 1, 6, and 13, defined by the minimum P values in the χ2 test of homogeneity (Tables 1, 2, and data not shown) are syntenic with human chromosomes 1q41-42, 7p21, and 5q23-35, respectively,21 an intriguing observation given that induced AML in humans commonly involves monosomy 7, 5q−, or both.4,5 Furthermore, because there is no statistically significant difference in the incidence of r-AML in 3 Gy X-irradiated (CBA/H × C57BL/6)F1 × CBA/H and (CBA/H × C57BL/6)F1 × C57BL/6 backcross mice,17 additional loci should be revealed in a genome-wide genetic linkage analysis of affected and unaffected (CBA/H × C57BL/6)F1 × C57BL/6 backcross mice.

Although each interval contains more than 100 genes, there must be a difference in the biologic activity of the susceptibility/resistance gene product(s) in the r-AML–susceptible and the r-AML–resistant mouse strains. Our current understanding of the radiation myeloid leukemogenic process suggests that the gene product(s) probably has a role in the regulation of the target LT-HSC, the cellular response to ionizing radiation and/or confer a proliferative advantage to the preleukemic LT-HSC. Furthermore, r-AML susceptibility/resistance loci do not appear to be involved in the leukemogenic process leading to mixed-lineage early to pre-B lymphomyeloid leukemia in the same irradiated backcross mice.

The stem cell frequency 1 locus (Scfr1), which determines the frequency of bone marrow long-term culture-initiating cells (LTC-IC) in inbred mice, maps to the interval between D1Mit113 (90 cM) and D1Mit17 (113 cM),25 a significant overlap with the 92.3 to 100 cM chromosome 1 interval defined by D1Mit111 and D1Mit150, which have the minimum P values in the genetic linkage analysis (Table 2). Because LTC-ICs are phenotypically and functionally indistinguishable from LT-HSCs25 and are therefore the target cell in r-AML, Scfr1 is an obvious candidate. Independent studies have shown that adult C57BL/6 mice have lower bone marrow LT-HSC numbers than other inbred mouse strains. For example, AKR/J mice have 5 times more LinThy-1low Sca-1+c-kit+bone marrow cells than C57BL/6 mice26; DBA/2 mice have 11 times more LTC-IC bone marrow cells than C57BL/6 mice25; and 8-week-old DBA mice have 2.75 times more day 35 cobblestone area-forming cells (CAFCs) than C57BL/6 mice.27,28 Given that the AML-susceptible inbred CBA/H mice used in this study are closely related to DBA/2 mice,29 which have higher numbers of LTC-ICs and day 35 CAFCs than the AML-resistant C57BL/6 strain,25,27,28 modest differences in stem cell numbers may contribute to the relative risk for induced AML. It is highly likely that the size of the stem cell compartment is regulated by multiple genes in addition to Scfr1 and that differences in cell survival and radiosensitivity following exposure to 3 Gy x-rays are a further potential factor in determining effective target size in the subsequent multistage leukemogenic process. Interindividual variation in bone marrow CD34+ stem and granulocyte macrophage–colony-forming unit (CFU-GM) progenitor cell numbers has been reported in humans,30-33 and though some of the variation observed may be caused by technical difficulties in the assays and the assays may not necessarily accurately reflect target LT-HSC numbers, the magnitude of the interindividual variation observed suggests that target size does vary within the human population.

The excess heterozygosity detected on chromosome 6 (Table 2) suggests the presence of a CBA/H r-AML resistance locus. However, loss of heterozygosity (LOH) studies did not detect allelic loss on chromosome 6 in r-AMLs34 (and data not shown), indicating that the locus does not appear to be subject to the inactivation processes normally associated with tumor-suppressor genes. More than 100 r-AMLs that arose in irradiated inbred CBA, C3H, RFM, and B6C3F1 genetic backgrounds have been analyzed for clonal chromosomal abnormalities by conventional G-banding or fluorescence in situ hybridization (FISH).35-39 As summarized in Table 1, allelic loss (terminal or interstitial deletions) on chromosome 2 is observed in more than 95% of r-AMLs, and aberrations on chromosome 6 represent the next most frequent clonal aberration (33.5%), followed by chromosome 15 (22%). Significantly, trisomy 6 (15%) is observed at a greater than 2-fold higher frequency than trisomy 15 (7.1%) or 1 (6%) and at a greater than 3.5-fold higher incidence than trisomy of any of the other 15 autosomes. Chromosomal abnormalities involving chromosome 15, and trisomy in particular, are frequently observed in mouse radiation-induced thymic lymphomas and have been implicated in tumor progression.40 In addition to the relative excess of chromosome 6 aberrations in the r-AMLs, an excess of CBA/H mouse bone marrow cells carrying aberrations of chromosomes 2 or 6 have also been reported in mice up to 6 months after exposure to 3 Gy x-rays,41 suggesting that these aberrations confer a proliferative advantage in vivo. This is consistent with the genetic analyses that indicate that though excess heterozygosity on chromosome 6 is neither necessary nor sufficient for radiation leukemogenesis, it does increase the RR of r-AML.

Ionizing radiation induces genetic instability in the clonal descendants of a single irradiated cell that persists for many cell generations in vitro and in vivo, so exposure potentially results in an elevated mutation rate.42,43 Radiation-induced genetic instability is induced at a higher efficiency in the clonal descendants of irradiated short-term repopulating HSCs (ST-HSCs) from the r-AML–susceptible CBA/H mouse than in ST-HSC from the r-AML–resistant C57BL/6 mouse, and it appears to be a recessive CBA/H genetic trait because it is induced at the lower efficiency in the (CBA/H × C57BL/6)F1 hybrid.44 A modest increase in mutation rate caused by a genetically determined susceptibility to radiation-induced genetic instability could result in a modest increase in the risk for r-AML without its being absolutely necessary for the radiation–leukemogenic process. Significantly, a genetic component to radiation-induced genetic instability has also been observed in human ST-HSC45 and ongoing chromosomal instability detected in mouse and human r-AML.36 46 

The genetic data presented here are further supportive17evidence that r-AML susceptibility in the CBA/H mouse model is a complex polygenic trait involving low-penetrance resistance and susceptibility loci. Because this is consistent with the proposal that most cancers and leukemias arise in a susceptible human subpopulation,3 the CBA/H mouse model may be more relevant to human-induced AML than might have been expected. Furthermore, the colocalization of the suggestive chromosome 1 r-AML susceptibility locus and Scfr1 raises the possibility that in addition to the number of genetic lesions required for malignant transformation and the mutation rate, target cell numbers may be part of the equation defining target size in oncogenesis. This is a provocative but testable hypothesis, and it has potential implications in our understanding of low-penetrance genetic risk factors.

Prepublished online as Blood First Edition Paper, October 31, 2002; DOI 10.1182/blood-2002-08-2394.

Supported by the Medical Research Council and by the Leukaemia Research Fund. C.C. and H.C. were supported by MRC Research Studentships.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Russo
A
Zanna
I
Tubiolo
C
et al
Hereditary common cancers: molecular and clinical genetics.
Anticancer Res.
20
2000
4841
4851
2
Emery
J
Lucassen
A
Murphy
M
Common hereditary cancers and implications for primary care.
Lancet.
358
2001
56
63
3
Peto
J
Houlston
RS
Genetics and the common cancers.
Eur J Cancer.
37
2001
S88
S96
4
Pedersen-Bjergaard
J
Pedersen
M
Roulston
D
Philip
P
Different genetic pathways in leukaemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia.
Blood.
86
1995
3542
3552
5
Devereux
S
Therapy associated leukemia.
Blood Rev.
5
1991
138
145
6
Pierce
DA
Shimizu
Y
Preston
DL
Vaeth
M
Mabuchi
K
Studies of the mortality of atomic bomb survivors. Report 12, Part I. Cancer: 1950-1990.
Radiat Res.
146
1996
1
27
7
Leone
G
Mele
L
Pulsoni
A
Equitani
F
Pagano
L
The incidence of secondary leukaemias.
Haematologica.
84
1999
937
945
8
Van Leeuwen
FE
Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment.
Baillieres Clin Haematol.
9
1996
57
85
9
Pedersen-Bjergaard
J
Andersen
MK
Christiansen
DH
Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation.
Blood.
95
2000
3273
3279
10
Latagliata
R
Petti
MC
Fenu
S
et al
Therapy-related myelodysplastic syndrome—acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem.
Blood.
99
2002
822
824
11
Allan
JM
Wild
CP
Rollinson
S
et al
Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.
Proc Natl Acad Sci U S A.
98
2001
11592
11597
12
Felix
CA
Walker
AH
Lange
BJ
et al
Association of CYP3A4 genotype with treatment-related leukemia.
Proc Natl Acad Sci U S A.
95
1998
13176
13181
13
Larson
RA
Wang
Y
Banerjee
M
et al
Prevalence of the inactivating 609C-T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.
Blood.
94
1999
803
807
14
Lebailly
P
Willett
EV
Moorman
AV
et al
Genetic polymorphisms in microsomal epoxide hydrolase and susceptibility to adult acute myeloid leukaemia with defined cytogenetic abnormalities.
Br J Haematol.
116
2002
587
594
15
Sasai
Y
Horiike
S
Misawa
S
et al
Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia.
Leuk Res.
23
1999
975
981
16
Mole
RH
Radiation-induced acute myeloid leukemia in the mouse: experimental observations in vivo with implications for hypotheses about the basis of carcinogenesis.
Leuk Res.
7
1986
859
865
17
Boulton
E
Cleary
H
Papworth
D
Plumb
M
Susceptibility to radiation-induced leukemia/lymphoma is genetically separable from sensitivity to radiation-induced genomic instability.
Int J Radiat Biol.
77
2001
21
29
18
Kaplan
HS
Brown
MB
A quantitative dose-response study of lymphoid-tumour development in irradiated C57 Black mice.
J Natl Cancer Inst.
13
1952
185
192
19
Cleary
H
Boulton
E
Plumb
M
Allelic loss on chromosome 4 (Lyr2/TLSR5) is associated with myeloid, B-lympho-myeloid and lymphoid (B & T) mouse radiation-induced leukemias.
Blood.
98
2001
1549
1554
20
Microsatellite primer sequences. Whitehead Institute. Available at:www-genome.wi.mit.edu
21
2000 Chromosome Committee Reports. Jackson Laboratory. Available at:www.informatics.jax.org
22
Mock
BA
Krall
MM
Dosik
JK
Genetic mapping of tumour susceptibility genes involved in mouse plasmacytomagenesis.
Proc Natl Acad Sci U S A.
90
1993
9499
9503
23
Thompson
GA
A review of theoretical aspects of HLA and disease associations.
Theor Popul Biol.
20
1987
168
208
24
Lander
E
Kruglyak
L
Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results.
Nat Genet.
11
1995
241
247
25
Muller-Sieburg
CE
Riblet
R
Genetic control of the frequency of haemopoietic stem cells in mice: mapping a candidate locus to chromosome 1.
J Exp Med.
183
1996
1141
1150
26
Morrison
SJ
Qian
D
Jerabek
L
et al
A genetic determinant that specifically regulates the frequency of hematopoietic stem cells.
J Immunol.
68
2002
635
642
27
De Haan
G
Nijhof
W
Van Zant
G
Mouse strain-dependent changes in frequency and proliferation of hematopoietic stem cells during aging: correlation between lifespan and cycling activity.
Blood.
89
1997
1543
1550
28
De Haan
G
Van Zant
G
Dynamic changes in mouse hematopoietic stem cell numbers during aging.
Blood.
93
1999
3294
3301
29
Festing
MFW
Origins and characteristics of inbred strains of mice.
Genetic variants and strains of the laboratory mouse.
3rd ed.
Lyon
MF
Rastan
S
Brown
SDM
2
1996
1537
1576
Oxford University Press
Oxford, England
30
Papadaki
HA
Gibson
FM
Gordon-Smith
EC
Marsh
JCW
Eliopoulos
GD
Assessment of bone marrow stem cell reserve and function and stromal cell function in patients with severe congenital neutropenia.
Eur J Haematol.
67
2001
245
251
31
Ferrero
D
Cherasco
C
Ortolano
B
Giaretta
F
Bruno
B
In vitro growth and quantification of early (CD33−/CD38−) myeloid progenitor cells: stem cell factor requirement and effects of previous chemotherapy.
Haematologica.
84
1999
390
396
32
Marley
SB
Lewis
JL
Davidson
RJ
et al
Evidence for continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children.
Br J Haematol.
106
1999
162
166
33
Smeland
EB
Funderud
S
Kvalheim
G
et al
Isolation and characterization of human hematopoietic progenitor cells: an effective method for positive selection of CD34+ cells.
Leukemia.
6
1992
845
852
34
Cleary
HJ
Wright
E
Plumb
M
Specificity of loss of heterozygosity in radiation-induced mouse myeloid and lymphoid leukemias.
Int J Radiat Biol.
75
1999
1223
1230
35
Hayata
I
Seki
M
Yoshida
K
et al
Chromosomal aberrations observed in 52 mouse myeloid leukemias.
Cancer Res.
43
1983
367
373
36
Macdonald
D
Boulton
E
Pocock
D
Goodhead
D
Kadhim
M
Plumb
M
Evidence of genetic instability in 3 Gy x-ray–induced mouse leukaemias and 3 Gy x-irradiated haemopoietic stem cells.
Int J Radiat Biol.
77
2001
1023
1031
37
Rithidech
KN
Bond
VP
Cronkite
EP
Thompson
MH
A specific chromosomal deletion in murine leukemic cells induced by radiation with different qualities.
Exp Hematol.
21
1993
427
431
38
Rithidech
K
Bond
VP
Cronkite
EP
et al
Hypermutability of mouse chromosome 2 during the development of x-ray-induced murine myeloid leukemia.
Proc Natl Acad Sci U S A.
92
1995
1152
1156
39
Breckon
G
Papworth
D
Cox
R
Murine radiation myeloid leukaemogenesis: a possible role for radiation-sensitive sites on chromosome 2.
Genes Chromosomes Cancer.
3
1991
367
375
40
McMorrow
LE
Newcomb
EW
Pellicer
A
Identification of a specific marker chromosome early in tumour development in γ-irradiated C57BL/6J mice.
Leukemia.
2
1988
115
119
41
Bouffler
SD
Breckon
G
Cox
R
Chromosomal mechanisms in murine radiation acute myeloid leukaemogenesis.
Carcinogenesis.
17
1996
655
659
42
Wright
EG
Radiation-induced genomic instability in haemopoietic cells.
Int J Radiat Biol.
74
1998
681
687
43
Morgan
WF
Day
JP
Kaplan
MI
McGhee
EM
Limoli
CL
Genomic instability induced by ionizing radiation.
Radiat Res.
146
1996
247
258
44
Watson
GE
Lorimore
SA
Clutton
SM
Kadhim
MA
Wright
EG
Genetic factors influencing α-particle–induced chromosomal instability.
Int J Radiat Biol.
71
1997
497
503
45
Kadhim
MA
Lorimore
SA
Hepburn
MD
Goodhead
DT
Buckle
VJ
Wright
EG
Alpha-particle–induced chromosomal instability in human bone marrow cells.
Lancet.
344
1994
987
988
46
Nakanishi
M
Tanaka
K
Shintani
T
Takahashi
T
Kamada
N
Chromosomal instability in acute myelocytic leukemia and myelodysplastic syndrome patients among atomic bomb survivors.
J Radiat Res.
40
1999
159
167

Author notes

Mark Plumb, Department of Genetics, University of Leicester, Leicester LE1 7RH, United Kingdom; e-mail:map12@le.ac.uk.

Sign in via your Institution